Lerdelimumab
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research[1][2].
Product Specifications
CAS Number
285985-06-0
Product Name Alternative
CAT-152
UNSPSC
12352203
Target
TGF-beta/Smad
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/lerdelimumab.html
Purity
97.27
Solubility
10 mM in DMSO
Smiles
[Lerdelimumab]
References & Citations
[1]Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44 (8) :3394-401.|[2]Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Badge
Hot
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TP308599L 1 mg
Oct-1 (POU2F1) (NM_002697) Human Recombinant Protein
Sign In for Pricing
View Details 
SPD-M196b-100ug 100 µg
Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA2 (AM130)
Sign In for Pricing
View Details 
